TY - JOUR
T1 - Influence of metabolic state and body composition on the action of pharmacological treatment of migraine
AU - Bruijn, Noor
AU - van Lohuizen, Romy
AU - Boron, Malgorzata
AU - Fitzek, Mira
AU - Gabriele, Francesca
AU - Giuliani, Giada
AU - Melgarejo, Laura
AU - Řehulka, Pavel
AU - Sebastianelli, Gabriele
AU - Triller, Paul
AU - Vigneri, Simone
AU - Özcan, Behiye
AU - van den Brink, Antoinette Maassen
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12/13
Y1 - 2024/12/13
N2 - Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected in patients with metabolic disease due to body composition and metabolic change. Therefore, the efficacy of antimigraine drugs could be altered in patients with both migraine and metabolic disease. However, knowledge of the pharmacology and the related clinical effects of antimigraine drugs in patients with metabolic disease are limited. Therefore, and given the clinical relevance, this article provides a comprehensive overview of the current research and hypotheses related to the influence of metabolic state and body composition on the action of antimigraine drugs. In addition, the influence of antimigraine drugs on metabolic functioning and, vice versa, the influence of metabolic diseases and its hormonal modulating medication on migraine activity is outlined. Future exploration on personalizing migraine treatment to individual characteristics is necessary to enhance therapeutic strategies, especially given its increasing significance in recent decades.
AB - Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected in patients with metabolic disease due to body composition and metabolic change. Therefore, the efficacy of antimigraine drugs could be altered in patients with both migraine and metabolic disease. However, knowledge of the pharmacology and the related clinical effects of antimigraine drugs in patients with metabolic disease are limited. Therefore, and given the clinical relevance, this article provides a comprehensive overview of the current research and hypotheses related to the influence of metabolic state and body composition on the action of antimigraine drugs. In addition, the influence of antimigraine drugs on metabolic functioning and, vice versa, the influence of metabolic diseases and its hormonal modulating medication on migraine activity is outlined. Future exploration on personalizing migraine treatment to individual characteristics is necessary to enhance therapeutic strategies, especially given its increasing significance in recent decades.
UR - http://www.scopus.com/inward/record.url?scp=85185114944&partnerID=8YFLogxK
U2 - 10.1186/s10194-024-01724-3
DO - 10.1186/s10194-024-01724-3
M3 - Review article
C2 - 38347465
AN - SCOPUS:85185114944
SN - 1129-2369
VL - 25
JO - Journal of Headache and Pain
JF - Journal of Headache and Pain
IS - 1
M1 - 20
ER -
